Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Diabetes

  • 1
    News

    ESC heart failure guideline to integrate bounty of new meds

    July 29, 2021

    It has a simple answer to a seemingly complex issue: how to merge the newly approved with mainstay drug therapies. And it conditionally okays meds in a group long without guideline-directed options.

  • 1
    News

    Unmanaged diabetes, high blood glucose tied to COVID-19 severity

    June 26, 2021

    Findings suggest in part that hospitalized COVID-19 patients need aggressive treatment of hyperglycemia, regardless of the diagnosis of diabetes or A1c value.

  • 1
    News

    Sotagliflozin use in T2D patients linked with posthospitalization benefits in analysis

    June 23, 2021

    The paper’s outcome measure may be a meaningful, patient-centered way of capturing disease burden, according to the authors.

  • News

    More obese, diabetic, chronically ill kids hospitalized with COVID-19

    June 16, 2021

    Children with diabetes, obesity, and cardiac and circulatory congenital anomalies were more likely to be hospitalized with COVID-19 and to be severely ill while hospitalized, a new study finds.

  • 1
    News

    Sotagliflozin’s HFpEF benefit confirmed by new analyses

    May 24, 2021

    A meta-analysis of two pivotal trials for the SGLT1/2 inhibitor sotagliflozin prospectively documents a HFpEF benefit.

  • 1
    News

    FIDELIO-DKD: Finerenone cuts new-onset AFib in patients with type 2 diabetes and CKD

    May 18, 2021

    A prespecified, exploratory analysis from the FIDELIO-DKD trial showed that the nonsteroidal MRA finerenone significantly cut new-onset AFib.

  • 1
    News

    Dapagliflozin misses as treatment for COVID-19 but leaves intriguing signal for benefit

    May 18, 2021

    The SGLT2 inhibitor dapagliflozin was not associated with significant benefit in COVID-19 patients but came close.

  • News

    In-hospital glucose management program gives dramatic savings

    May 10, 2021

    “I’ve been advocating for endocrine hospitalists to be deployed nationally,” said Dr. Misha Zilbermint.

  • News

    Most kids with type 1 diabetes and COVID-19 in U.S. fared well

    May 3, 2021

    Most children who were hospitalized had diabetic ketoacidosis (DKA) and high A1c levels.

  • News

    High obesity rates in Southern states magnify COVID threats

    March 19, 2021

    At least 29 states have green-lighted obesity for inclusion in the first phases of the COVID-19 vaccine rollout. That could overwhelm government efforts and heighten competition for scarce doses.

Previous1 2 3 4 5 … 14Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
fa-facebookfa-linkedinfa-instagramfa-youtube-playfa-commentfa-envelopefa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences